Denise Calaprice-Whitty, PhD
After receiving her Bachelor’s degree in Biology from Harvard University and her MS and PhD from Princeton, Dr. Denise Calaprice-Whitty became an NIH fellow at Columbia University’s College of Physicians and Surgeons in the departments of Clinical and Genetic Epidemiology and Child Psychiatry. During her time at Columbia, her research on the psychoneuroimmunology of childhood anxiety and mood disorders led to the prestigious Young Investigator Award from NARSAD (National Alliance for Research on Schizophrenia and Depression). Although she continues to work and publish in this field as an avocation, her post-Columbia career led her into industry, where she has spent more than two decades designing and directing clinical research programs and creating innovative development and operational strategies in a variety of settings. Her positions have included Senior Director of Immunology Therapeutics at IQVIA (then Quintiles), Head of Clinical Research for North America at Altana/BykGulden, and Senior Director of Clinical Research at Regeneron. Dr. Calaprice has been consulting since 2006, including high-profile engagements with the Department of Defense under the Obama Administration (optimizing defense against biological warfare); with industry consortia such as The Avoca Quality Consortium, the Avoca Innovation Alliance, and Metrics Champion Consortium; and with numerous individual companies from the biggest international pharma to Silicon Valley start-ups and incubators. Among her many accomplishments in this capacity, Dr. Calaprice developed the novel metrics taxonomy that was used by Pfizer to optimize its clinical research operations in the years just prior to Covid, and that has now been adopted by many of the world’s most prominent pharma. She has presented to FDA about her industry research and innovations, and on behalf of a variety of specific immunotherapies, on numerous occasions; and publishes and presents frequently for both medical and industry publications and conferences.